New Molecules to Fight Prostate Cancer
Peptoid conjugates targeting prostate cancer
['FUNDING_R01'] · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · NIH-11159600
This research explores new protein-like molecules that can stop the growth of prostate cancer cells, especially those that no longer respond to current treatments.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NEW YORK UNIVERSITY SCHOOL OF MEDICINE (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11159600 on ClinicalTrials.gov |
What this research studies
Many prostate cancers rely on a hormone pathway, but over time, they can become resistant to standard treatments. This project is developing a new type of molecule, called a multivalent peptoid conjugate (MPC), designed to block this hormone pathway in a different way. These MPCs are like small, stable protein chains that can effectively stop the growth of prostate cancer cells, even those that have become resistant to current medications. We believe these molecules work by changing how cancer cells use their hormone receptors, and they may also help the body's immune system recognize and fight the tumor.
Who could benefit from this research
Good fit: Patients with prostate cancer, particularly those whose cancer has become resistant to standard anti-androgen treatments like enzalutamide, would be the focus of this research.
Not a fit: Patients with early-stage prostate cancer that is still responsive to current treatments, or those with other types of cancer, may not directly benefit from this specific approach.
Why it matters
Potential benefit: If successful, this could offer a new treatment option for patients with advanced prostate cancer that has become resistant to existing therapies.
How similar studies have performed: Preliminary studies have shown that these new molecules can deter prostate cancer growth, suggesting a promising novel approach.
Where this research is happening
NEW YORK, UNITED STATES
- NEW YORK UNIVERSITY SCHOOL OF MEDICINE — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GARABEDIAN, MICHAEL J. — NEW YORK UNIVERSITY SCHOOL OF MEDICINE
- Study coordinator: GARABEDIAN, MICHAEL J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.